Pfizer On Boosters, Kids And Prospects For A Long-Term COVID-19 Business

Jul 28 2021

• By Jessica Merrill

Listen to this article

The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.

Money gold coins — Pfizer raised its guidance for its COVID-19 vaccine. • Source: Alamy

Pfizer Inc.'s COVID-19 vaccine BNT162b2, developed in partnership with BioNTech SE, has reshaped the company's financial outlook and management expects the vaccine business will continue to be a contributor for the foreseeable future. One of the outstanding questions about the long-term viability of the business is if regulator booster shots will be needed, and Pfizer, at least, believes that may be the case.

The firm raised its financial guidance for the vaccine this year to $33bn versus a prior guidance of $26bn, a...

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain
Aug 22 2024
• By Alaric DeArment
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy
Aug 16 2024
• By Alaric DeArment
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
AstraZeneca Moves To Join Invyvid In COVID-19 Prevention
Jul 04 2024
• By Elizabeth Cairns
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
Stock Watch: Thoroughly Moderna Missteps
Jun 18 2024
• By Andy Smith
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj